Lauren Creel

Lauren represents startups from formation through exit, including in pivotal private financing transactions, entity formation and governance matters. She works closely with startups in healthcare, life sciences, biotech, medtech, digital health and medical devices, as well as general technology. Her clients include Alumis, Archive Resale, Cala Health, Carmot Therapeutics, Kriya Therapeutics, NGM Bio, Path Robotics and Science Corporation, with deals ranging from Series Seed to Series G. In addition, she counsels venture capital investors and strategic investors investing in healthcare and life sciences as well as in technology generally. Her clients include Axon Capital, Overwater Ventures, Santé Ventures and Sonder Capital.

Lauren’s recent experience includes advising:

• Alumis on its $90 million Series B-2 and $259 million Series C financings as well as its $250 million initial public offering (IPO)
• Archive Resale on its Series Seed, $15 million Series A and $30 million Series B financings
• Cala Health on its $50 million Series C financing
• Carmot Therapeutics on its $150 million Series E financing, potential IPO as the company explored a dual-track process and acquisition by Roche for $2.7 billion
• Glide Software on its $15 million Series A financing
• Kriya Therapeutics on its more than $430 million Series C and $320 million Series D financings
• Lyell Immunopharma on its $493 million Series C financing and $425 million IPO
• NGM Bio on its $122 million Series A financing
• Path Robotics on its $56 million Series B, $100 million Series C and $100 million Series D financings
• RefleXion Medical on its $80 million Series E and $105 million Series F financings
• Science Corporation on its $104 million convertible promissory note financing